Most studies have reported that the use of anti-TNF agents during pregnancy in patients with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis does not increase the occurrence of adverse maternal or infant outcomes (65), although there is a higher risk of infections in patients exposed to anti-TNFα (66). Here, TNF is linked to inflammatory bowel disease.